• 1
    Bikle DD 1988 Effects of alcohol abuse on bone. Compr Ther 14:1620.
  • 2
    Bikle DD, Genant HK, Cann C, Recker RR, Halloran BP, Strewler GJ 1985 Bone disease in alcohol abuse. Ann Intern Med 103:4248.
  • 3
    Feitelberg S, Epstein S, Ismail F, D'Amanda C 1987 Deranged bone mineral metabolism in chronic alcoholism. Metabolism 36:322326.
  • 4
    Lalor BC, France MW, Powell D, Adams PH, Counihan TB 1986 Bone and mineral metabolism and chronic alcohol abuse. Q J Med 59:497511.
  • 5
    Laitinen K, Lamberg-Allardt C, Tunninen R, Harkonen M, Valimaki M 1992 Bone mineral density and abstention-induced changes in bone and mineral metabolism in noncirrhotic male alcoholics. Am J Med 93:642650.
  • 6
    Riggs BL 1987 Pathogenesis of osteoporosis. Am J Obstet Gynecol 156:13421346.
  • 7
    Slemenda CW, Christian JC, Reed T, Reister TK, Williams CJ, Johnston CC Jr 1992 Long-term bone loss in men: Effects of genetic and environmental factors. Ann Intern Med 117:286291.
  • 8
    Friday KE, Howard GA 1991 Ethanol inhibits human bone cell proliferation and function in vitro. Metabolism 40:562565.
  • 9
    Johnell O, Nilsson BE, Wiklund PE 1982 Bone morphometry in alcoholics. Clin Orthop 165:253258.
  • 10
    Diamond T, Stiel D, Lunzer M, Wilkinson M, Posen S 1989 Ethanol reduces bone formation and may cause osteoporosis. Am J Med 86:282288.
  • 11
    Farley JR, Fitzsimmons R, Taylor AK, Jorch UM, Lau KH 1985 Direct effects of ethanol on bone resorption and formation in vitro. Arch Biochem Biophys 238:305314.
  • 12
    Baran DT, Teitelbaum SL, Bergfeld MA, Parker G, Cruvant EM, Avioli LV 1980 Effect of alcohol ingestion on bone and mineral metabolism in rats. Am J Physiol 238:E507E510.
  • 13
    Cheung RC, Gray C, Boyde A, Jones SJ 1995 Effects of ethanol on bone cells in vitro resulting in increased resorption. Bone 16:143147.
  • 14
    Teitelbaum SL 2000 Bone resorption by osteoclasts. Science 289:5041508.
  • 15
    Suda T, Udagawa N, Takahashi K 1996 Osteoclast generation. In: BilezikianJP, RaiszLG, RodanGA (eds.) Principles of Bone Biology. Academic Press, Inc., San Diego, CA, USA, pp. 87102.
  • 16
    Diez A, Puig J, Serrano S, Marinoso ML, Bosch J, Marrugat J, Mellibovsky L, Nogues X, Knobel H, Aubia J 1994 Alcohol-induced bone disease in the absence of severe chronic liver damage. J Bone Miner Res 9:825831.
  • 17
    Dai J, Lin D, Zhang J, Habib P, Smith P, Murtha J, Fu Z, Yao Z, Qi Y, Keller ET 2000 Chronic alcohol ingestion induces osteoclastogenesis and bone loss through IL-6 in mice. J Clin Invest 106:887895.
  • 18
    Watzl B, Lopez M, Shahbazian M, Chen G, Colombo LL, Huang D, Way D, Watson RR 1993 Diet and ethanol modulate immune responses in young C57BL/6 mice. Alcohol Clin Exp Res 17:623630.
  • 19
    Wang Y, Watson RR 1994 Chronic ethanol consumption prior to retrovirus infection alters cytokine production by thymocytes during murine AIDS. Alcohol 11:361365.
  • 20
    Jilka RL, Weinstein RS, Takahashi K, Parfitt AM, Manolagas SC 1996 Linkage of decreased bone mass with impaired osteoblastogenesis in a murine model of accelerated senescence. J Clin Invest 97:17321740.
  • 21
    Lee SK, Goldring SR, Lorenzo JA 1995 Expression of the calcitonin receptor in bone marrow cell cultures and in bone: A specific marker of the differentiated osteoclast that is regulated by calcitonin. Endocrinology 136:45724581.
  • 22
    Kimmel DB, Bozzato RP, Kronis KA, Coble T, Sindrey D, Kwong P, Recker RR 1993 The effect of recombinant human (1–84) or synthetic human (1–34) parathyroid hormone on the skeleton of adult osteopenic ovariectomized rats. Endocrinology 132:15771584.
  • 23
    Parfitt AM, Drezner MK, Glorieux FH, Kanis JA, Malluche H, Meunier PJ, Ott SM, Recker RR 1987 Bone histomorphometry: Standardization of nomenclature, symbols, and units. Report of the ASBMR Histomorphometry Nomenclature Committee. J Bone Miner Res 2:595610.
  • 24
    Haeckel R, Bucklitsch I 1987 The comparability of ethanol concentrations in peripheral blood and saliva. The phenomenon of variation in saliva to blood concentration ratios. J Clin Chem Clin Biochem 25:199204.
  • 25
    Winek CL, Esposito FM 1987 The validity of urine alcohol analysis in drunk drivers. Leg Med 97106.
  • 26
    Fuller K, Wong B, Fox S, Choi Y, Chambers TJ 1998 TRANCE is necessary and sufficient for osteoblast-mediated activation of bone resorption in osteoclasts. J Exp Med 188:9971001.
  • 27
    Nakashima T, Kobayashi Y, Yamasaki S, Kawakami A, Eguchi K, Sasaki H, Sakai H 2000 Protein expression and functional difference of membrane-bound and soluble receptor activator of NF-kappaB ligand: Modulation of the expression by osteotropic factors and cytokines. Biochem Biophys Res Commun 275:768775.
  • 28
    Jilka RL, Weinstein RS, Bellido T, Roberson P, Parfitt AM, Manolagas SC 1999 Increased bone formation by prevention of osteoblast apoptosis with parathyroid hormone. J Clin Invest 104:439446.
  • 29
    Simonet WS, Lacey DL, Dunstan CR, Kelley M, Chang MS, Luthy R, Nguyen HQ, Wooden S, Bennett L, Boone T, Shimamoto G, DeRose M, Elliott R, Colombero A, Tan HL, Trai LG, Sullivan J, Davy E, Bucay N, Renshaw-Gegg L, Hughes TM, Hill D, Pattison W, Campbell P, Boyle WJ 1997 Osteoprotegerin: A novel secreted protein involved in the regulation of bone density. Cell 89:309319.
  • 30
    Yasuda H, Shima N, Nakagawa N, Mochizuki SI, Yano K, Fujise N, Sato Y, Goto M, Yamaguchi K, Kuriyama M, Kanno T, Murakami A, Tsuda E, Morinaga T, Higashio K 1998 Identity of osteoclastogenesis inhibitory factor (OCIF) and osteoprotegerin (OPG): A mechanism by which OPG/OCIF inhibits osteoclastogenesis in vitro. Endocrinology 139:13291337.
  • 31
    Bateman TA, Dunstan CR, Ferguson VL, Lacey DL, Ayers RA, Simske SJ 2000 Osteoprotegerin mitigates tail suspension-induced osteopenia. Bone 26:443449.
  • 32
    Min H, Morony S, Sarosi I, Dunstan CR, Capparelli C, Scully S, Van G, Kaufman S, Kostenuik PJ, Lacey DL, Boyle WJ, Simonet WS 2000 Osteoprotegerin reverses osteoporosis by inhibiting endosteal osteoclasts and prevents vascular calcification by blocking a process resembling osteoclastogenesis. J Exp Med 192:463474.
  • 33
    Bolon B, Carter C, Daris M, Morony S, Capparelli C, Hsieh A, Mao M, Kostenuik P, Dunstan CR, Lacey DL, Sheng JZ 2001 Adenoviral delivery of osteoprotegerin ameliorates bone resorption in a mouse ovariectomy model of osteoporosis. Mol Ther 3:197205.
  • 34
    Bekker PJ, Holloway D, Nakanishi A, Arrighi M, Leese PT, Dunstan CR 2001 The effect of a single dose of osteoprotegerin in postmenopausal women. J Bone Miner Res 16:348360.
  • 35
    Capparelli C, Kostenuik PJ, Morony S, Starnes C, Weimann B, Van G, Scully S, Qi M, Lacey DL, Dunstan CR 2000 Osteoprotegerin prevents and reverses hypercalcemia in a murine model of humoral hypercalcemia of malignancy. Cancer Res 60:783787.
  • 36
    Zhang J, Dai J, Qi Y, Lin DL, Smith P, Strayhorn C, Mizokami A, Fu Z, Westman J, Keller ET 2001 Osteoprotegerin inhibits prostate cancer-induced osteoclastogenesis and prevents prostate tumor growth in the bone. J Clin Invest 107:12351244.
  • 37
    Honore P, Luger NM, Sabino MA, Schwei MJ, Rogers SD, Mach DB, O'Keefe PF, Ramnaraine ML, Clohisy DR, Mantyh PW 2000 Osteoprotegerin blocks bone cancer-induced skeletal destruction, skeletal pain and pain-related neurochemical reorganization of the spinal cord. Nat Med 6:521528.
  • 38
    Luger NM, Honore P, Sabino MA, Schwei MJ, Rogers SD, Mach DB, Clohisy DR, Mantyh PW 2001 Osteoprotegerin diminishes advanced bone cancer pain. Cancer Res 61:40384047.
  • 39
    Morony S, Capparelli C, Sarosi I, Lacey DL, Dunstan CR, Kostenuik PJ 2001 Osteoprotegerin inhibits osteolysis and decreases skeletal tumor burden in syngeneic and nude mouse models of experimental bone metastasis. Cancer Res 61:44324436.
  • 40
    Clohisy DR, Ramnaraine ML, Scully S, Qi M, Van G, Tan HL, Lacey DL 2000 Osteoprotegerin inhibits tumor-induced osteoclastogenesis and bone tumor growth in osteopetrotic mice. J Orthop Res 18:967976.
  • 41
    Pepersack T, Fuss M, Otero J, Bergmann P, Valsamis J, Corvilain J 1992 Longitudinal study of bone metabolism after ethanol withdrawal in alcoholic patients. J Bone Miner Res 7:383387.
  • 42
    Morony S, Capparelli C, Lee R, Shimamoto G, Boone T, Lacey DL, Dunstan CR 1999 A chimeric form of osteoprotegerin inhibits hypercalcemia and bone resorption induced by IL-1beta, TNF-alpha, PTH, PTHrP, and 1, 25(OH)2D3. J Bone Miner Res 14:14781485.
  • 43
    Emery JG, McDonnell P, Burke MB, Deen KC, Lyn S, Silverman C, Dul E, Appelbaum ER, Eichman C, DiPrinzio R, Dodds RA, James IE, Rosenberg M, Lee JC, Young PR 1998 Osteoprotegerin is a receptor for the cytotoxic ligand TRAIL. J Biol Chem 273:1436314367.
  • 44
    Truneh A, Sharma S, Silverman C, Khandekar S, Reddy MP, Deen KC, McLaughlin MM, Srinivasula SM, Livi GP, Marshall LA, Alnemri ES, Williams WV, Doyle ML 2000 Temperature-sensitive differential affinity of TRAIL for its receptors. DR5 is the highest affinity receptor. J Biol Chem 275:2331923325.
  • 45
    Kido J, Yamauchi N, Ohishi K, Kataoka M, Nishikawa S, Nakamura T, Kadono H, Ikedo D, Ueno A, Nonomura N, Okuyama A, Nagata T 1997 Inhibition of osteoblastic cell differentiation by conditioned medium derived from the human prostatic cancer cell line PC-3 in vitro. J Cell Biochem 67:248256.